Ignite Creation Date:
2024-05-06 @ 8:22 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06356584
Status:
RECRUITING
Last Update Posted:
2024-04-10
First Post:
2024-04-05
Brief Title:
Sintilimab Combined With FruquintinibRegorafenib Radiotherapy for Third-line Treatment of Advanced Metastatic Colorectal Cancer
Sponsor:
Shandong Cancer Hospital and Institute
Organization:
Shandong Cancer Hospital and Institute
Organization Data
Organization:
Shandong Cancer Hospital and Institute
Class:
OTHER
Study ID:
SDZLEC2024-078-01
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Shandong Cancer Hospital and Institute
Lead Sponsor Class:
OTHER
Responsible Party:
Jinbo Yue
Responsible Party Title:
Shandong Cancer Hospital Ethics Committee
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Shandong Cancer Hospital and Institute
Old Name:
None
Old Organization:
None